Pharmacogenomics

Genetic polymorphisms in very important pharmacogenomic (VIP) variants in the Tibetan population

T. B. Jin, Xun, X. J., Shi, X. G., Yuan, D. Y., Feng, T., Geng, T. T., and Kang, L. L., “Genetic polymorphisms in very important pharmacogenomic (VIP) variants in the Tibetan population”, vol. 14, pp. 12497-12504, 2015.

Genetic polymorphisms of very important pharmacogenomic (VIP) variants are important for personalized medicine. However, these have not been extensively studied in the Tibetan population. In this study, 82 VIP variants were detected in the Tibetan and Han (HAN) populations from northwestern China.

Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients

L. Wang, Liu, L. H., Tong, W. H., Wang, M. X., and Lu, S. C., “Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients”, vol. 14, pp. 15148-15157, 2015.

We examined the influence of the cytochrome P450 3A5 (CYP3A5) genes in both donors and recipients on the concentration-dosage ratio (C/D) of tacrolimus in Chinese liver transplant patients. Fifty-one adult liver transplant patients who received tacrolimus were included in this study. The CYP3A5 polymorphism in donors and recipients was determined at the time of transplantation, and tacrolimus-based immunosuppressive therapy was started based on each patient’s genetic constitution.

Subscribe to Pharmacogenomics